MaxCyte, Inc.
MXCT
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assaysā¦ read more
Healthcare
Medical Devices
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.56
Price+0.32%
$0.01
1Y
Price
Market Cap
$165.878m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-169.4%
EBITDA Margin-181.8%
Net Profit Margin-113.6%
Free Cash Flow Margin-169.4%
EBITDA Margin-181.8%
Net Profit Margin-113.6%
Free Cash Flow MarginRevenue
$34.419m
-10.9%
1y CAGR-8.0%
3y CAGR+1.6%
5y CAGREarnings
-$45.631m
-11.1%
1y CAGR-26.8%
3y CAGR-26.0%
5y CAGREPS
-$0.44
-12.8%
1y CAGR-37.7%
3y CAGR-24.8%
5y CAGRBook Value
$180.275m
$213.476m
Assets$33.201m
Liabilities$18.161m
DebtDebt to Assets
8.5%
-0.4x
Debt to EBITDAFree Cash Flow
-$41.226m
-40.9%
1y CAGR-10.8%
3y CAGR-40.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company